Kawasaki Disease (MCLS) Clinical Trials and Treatments

Kawasaki disease (KD) is an acute self-limited vasculitis of medium-sized arteries that predominantly affects infants and young children, particularly those under age 5 years. The exact etiology remains unknown but likely involves infectious triggers (viral superantigens, streptococcal peptides) in genetically susceptible individuals. Pathophysiology involves immune-mediated endothelial inflammation of coronary, cerebral, and mesenteric arteries.

The most common symptoms of Kawasaki Disease include Persistent fever lasting 5+ days, Bilateral conjunctival injection without exudate, Oral mucosa changes and strawberry tongue, Polymorphous rash on trunk and extremities, Extremity edema and erythema, among others. Kawasaki Disease affects approximately 1 in 100 to 1,000 children under age 5; highest in Asian populations. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Kawasaki Disease from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Early diagnosis and immediate treatment with intravenous immunoglobulin (IVIG, 2 g/kg) plus high-dose aspirin (80-100 mg/kg/day) are essential and must begin within 10 days of fever onset for optimal efficacy. Cardiac echocardiography at diagnosis, 2 weeks, and 8 weeks post-treatment assess coronary involvement and guide follow-up.

As of September 2026, Trial Friend's curated drug index does not include an FDA-approved treatment specific to Kawasaki Disease. The Treatments section of this page checks FDA drug labels live and lists any approved drug whose label names the condition, and the trials listed below cover the investigational options.

The exact cause of Kawasaki Disease is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. An ITPKC variant and other immune-gene variants raise risk and siblings have about tenfold higher risk, but no diagnostic gene test exists. The condition affects approximately 1 in 100 to 1,000 children under age 5; highest in Asian populations. Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Kawasaki Disease. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. An ITPKC variant and other immune-gene variants raise risk and siblings have about tenfold higher risk, but no diagnostic gene test exists.

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Kawasaki Disease clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Kawasaki Disease clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.